In closing, this scoping review mapped the changing landscapes of ICI-induced endocrinopathies before and after marketing of 1 anti-CTL4–1 mAb (approved 2011), 2 anti-PD-1 mAbs (approved 2014) and 3 anti-PDL-1 mAbs (approved 2016/2017). The gene discussed is CD274; the disease is endocrine system disorder.